CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced that it will discuss its drug discovery and development programs and provide a general corporate overview at the 12th Annual BIO CEO & Investor Conference on Monday, February 8, at 11:00 a.m. EST at the Waldorf Astoria Hotel in New York.
